en · de · es
selank-notes.peptides3081.com › Guide › Analytical Methods And Storage Stability — Quick Reference

Analytical Methods And Storage Stability — Quick Reference

By Editorial Desk · published 2026-02-12 · last reviewed 2026-02-28 · Guide

GABA-A receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.

Analytical Methods And Storage Stability

Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.

Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.

Selank Origin and Chemical Identity

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank at a glance

PropertyValueNotes
Typical storage temperature-20 °C or belowFor lyophilized powder, long term
Common analytical methodReverse-phase HPLCUsually paired with mass spectrometry
Typical reported purityAt or above 95 percent by areaResearch-grade material
Aqueous solubilityHighSolutions used in laboratory assays
Moisture sensitivityHydrolyzes in solutionAseptic handling reduces degradation

Proposed Mechanisms and Research Endpoints

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Related pages on this site

Analytical Methods and Material Handling

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Mechanism and Evidence Base

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Supporting material

The British Lions were regular visitors to South Africa until the 1980s, and the less formally segregated colony long before that. They would alternate these tours with tours to Australia and/or New Zealand. In the years 1948–1980, the Lions made five tours to South Africa, more or less one for every decade, and half of their total ten tours in this period. Their first tour in the apartheid period was in 1955, seven years after the formal inauguration of apartheid. They made further tours in 1962, 1968, 1974 and one final one in 1980. The controversy caused by this matter meant that the Lions did not go back there until their 1997 tour when the South Africa team was ostensibly mixed. The Lions would have toured South Africa in 1986 if the regular schedule had been kept to, but in December 1985 the South African Rugby Board announced they would not be inviting the Lions to tour the following year. Political objections to South Africa's apartheid policies including a potential boycott of the 1986 Commonwealth Games and state of emergency in South Africa at the time lay behind this decision. The squad selected for an International Rugby Board centenary match was the closest thing to an official 1986 British Lions side. It was managed by Clive Rowlands and coached by Mick Doyle. The 21 players selected were issued with Lions' blazers and ties and considered to be official British Lions.

ribozyme An RNA molecule with enzymatic activity, i.e. one that is capable of catalyzing one or more specific biochemical reactions, similar to protein enzymes. Ribozymes function in numerous capacities, including in ribosomes as part of the large subunit ribosomal RNA.

== Medical uses == In July 2021, azvudine became conditionally approved in China for the following indication: "to treat high-viral-load cases of HIV-1, in combination with a nucleoside reverse-transcriptase inhibitor and a non-nucleoside reverse-transcriptase inhibitor". The approval text describes it as a dual reverse transcriptase and Vif inhibitor. In July 2022, azvudine received emergency conditional approval for COVID-19 in adults. It is believed to work by inhibiting the RNA-dependent RNA polymerase (RdRp) enzyme in the SARS-CoV-2 virus.

Sources: en.wikipedia.org

Notes from published material

Keloids grow extensively beyond the wound margins and tend to persist or even worsen over time. They are relatively difficult to treat due to their high risk of recurrence. Keloids are more common in people with darker skin tones and often occur in individuals with a genetic predisposition. Keloids are the most extreme type of scarring since minor wounds such as insect bites or piercings can all lead to an elevated tissue area. Patients may experience psychological trauma if their scars are not well-controlled. Therefore, the prevention of wound formation is crucial to them. They should avoid undergoing any unnecessary invasive procedures or cosmetic surgeries. The beneficial effects of silicone gel sheeting on the treatment and prevention of these two scars have been confirmed. Since most patients develop hypertrophic and keloid scars within 3 months after surgery or injury, the silicone gel sheeting therapy should be started in the early repair phase to achieve an optimal therapeutic effect. The maturity of scars takes over a year; therefore, silicone treatment is also effective in scars aged over 12 months. The therapy usually requires 6 to 12 months of constant wear to achieve optimum results. Recent data suggest that the combination of silicone gel sheeting and pressure therapy can improve post-traumatic scar healing.

=== Neovascular glaucoma === Anti-VEGF agents as injectable medications, along with other standard of care treatment for decreasing intraocular pressure, may improve pressure in people with neovascular glaucoma for short periods. Evidence suggests that this improvement may last 4–6 weeks. There is no sufficient evidence to suggest that anti-VEGF medications are effective either for short-term or for longer-term treatment. The short, medium, and long-term safety of anti-VEGF treatment has not been well investigated.

== History == In 1834, Théophile-Jules Pelouze distilled tartaric acid and isolated glutaric acid and another unknown organic acid. Jöns Jacob Berzelius characterized this other acid the following year and named pyruvic acid because it was distilled using heat. The correct molecular structure was deduced by the 1870s.

Sources: en.wikipedia.org

Frequently asked questions

How is Selank detected in a laboratory?

The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.

What storage conditions are typical for Selank?

Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.

Does high reported purity guarantee correct identity?

No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.

What is Selank?

Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.

Network